Enzalutamide vs Abiraterone: Which is Better in Patients With Metastatic Castration-Sensitive Prostate Cancer? Edited by Katie Lennon

https://www.medscape.com/viewarticle/enzalutamide-vs-abiraterone-which-better-patients-metastatic-2026a1000rhc?src= Enzalutamide and abiraterone demonstrate comparable overall survival, time to treatment switch, and prostate cancer survival in patients with metastatic castration-sensitive prostate cancer (mCSPC). Among patients aged at least 75 years, enzalutamide was associated with improved overall survival compared with abiraterone, with a 3-year restricted mean survival time (RMST) difference of 1.65 months.